2022
DOI: 10.1016/j.isci.2022.104753
|View full text |Cite
|
Sign up to set email alerts
|

Metabolic labeling of the bacterial peptidoglycan by functionalized glucosamine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(16 citation statements)
references
References 79 publications
0
14
0
Order By: Relevance
“…32 As has been previously shown in OleD-expressing E. coli, UDP-GlcNAz is used by MurG to generate lipid II. 24 Figure 3. FACE gel of peptidoglycan sacculi.…”
Section: ■ Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…32 As has been previously shown in OleD-expressing E. coli, UDP-GlcNAz is used by MurG to generate lipid II. 24 Figure 3. FACE gel of peptidoglycan sacculi.…”
Section: ■ Resultsmentioning
confidence: 99%
“…23 Using 2-chloro-4-nitrophenyl GlcNAz in E. coli expressing OleD, the authors were able to demonstrate the in situ production of UDP-GlcNAz and subsequent incorporation of GlcNAz into peptidoglycans. 24 In another approach, we have used the promiscuous Bifidobacterial enzyme NahK to generate a set of C6-modified UDP-GlcNAc derivatives in vivo as glycosyltransferase inhibitors. 25 NahK is a GlcNAc 1-kinase with a high tolerance for synthetic and modified substrates including GlcNAz 26,27 and has been used in chemoenzymatic syntheses of various 1-phosphosugars.…”
Section: ■ Introductionmentioning
confidence: 99%
“…[36,37,41] Furthermore, Lipid II analogues with an azido moiety on C6 of GlcNAc were well tolerated by PGTs in vitro. [40] Recently, C2 N-acetyl-modified MurNAc and GlcNAc probes have been used for metabolic labelling of peptidoglycan in live bacteria, [42,43] which implies that bacterial PGTs can tolerate these particular modifications for glycan polymerisation.…”
Section: Glycanmentioning
confidence: 99%
“…Correspondingly, several crystal and CryoEM structures of MoeA-bound PGTs (i. e., aPBPs and MGTs) revealed that MoeA resides in the glycosyl donor site and its carbohydrate and 3-PG moieties are extensively hydrogen bonded to a number of residues in the active site, locking the PGT into an inactive conformation. [49,50,[56][57][58][59][60] Given the strict substrate lipid requirement of the PGTs' donor sites, it remains unclear how the C 25 lipid of MoeA with unnatural double bond Lipid II probes can be created by modifying Lipid II on one or more of the following sites: N-acetyl groups on either sugar, [42,43] C6 on GlcNAc, [40] the terminus of the lipid tail, [38,39] and the third-fifth amino acids of the stem peptide. [32,38,39,44,45,48] geometry interacts with PGTs, as the molecular details are not resolved in current structural studies.…”
Section: Moenomycin a A Natural Product Inhibitor Of Pgtsmentioning
confidence: 99%
See 1 more Smart Citation